Introducing ValueOptions Clinical Care Alerts

Similar documents
FL Medicaid Drug Therapy Management Program for Behavioral Health Monitoring for Safety and Quality

Preferred Practice Guidelines Bipolar Disorder in Children and Adolescents

Psychiatric Care. Course Goals

Performance Outcomes: Measure & Metric Details

Outpatient use of Atypical Antipsychotic Agents in the Pediatric Population Years

Evaluation of a Medicaid Psychotropic Drug Management Program in Utah

Depression: Assessment and Treatment For Older Adults

Exhibit I-1 Performance Measures. Numerator (general description only)

Pharmacy Prior Authorization GMH/SA and Non-Title 19/21 SMI Non-Formulary and Prior Authorization Guidelines

Care Management Technologies

Alberta Alcohol and Drug Abuse Commission. POSITION ON ADDICTION AND MENTAL HEALTH February 2007

METHODS RESULTS. Supported by funding from Ortho-McNeil Janssen Scientific Affairs, LLC

Jan Feb Mar Apr May Jun Jul Aug Sep X X X X X X X. Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov X X X X X X X X X X X X X

KEY BEHAVIORAL MEASURES

Guidelines for the Utilization of Psychotropic Medications for Children in Foster Care. Illinois Department of Children and Family Services

Use of Anti-Psychotic Agents in Irish Long Term Care Residents with Dementia

Hedis Behavioral Health Measures

Key Behavioral Health Measures (18 Years and Older)

Treatment Options for Bipolar Disorder Contents

Promoting and Monitoring Evidenced-Based Antipsychotic Prescribing Practices in Children and Adolescents: Florida Medicaid Initiatives

The Louis de la Parte Florida Mental Health Institute

Child and Adolescent Psychiatry Trends. ADAMHS Board - 28 Oct 2014

Key Behavioral Measures (17 Years and Younger)

9/25/15. Pharmacy Quality Measures: Financial Support. Learning Objectives. Speaker Disclosure. Access to Preferred Networks and Clinical Performance

A COMPREHENSIVE APPROACH TO MANAGING DIABETES

Pediatric Behavioral Health Medication Initiative Prior Authorization (PA) Request Form

Application of EventFlow to Model the Complexity and Continuity of Antipsychotic Use Among Youth

Children On Psychotropic Medications

Unmanaged Behavioral Health Puts Your Company At Risk. Presented by: Dr. Sam Mayhugh Integrated Behavioral Health

Medi Cal Managed Care. Melissa Lamer, PharmD, BCPP July 31 st, 2014

POLYPHARMACY. A practical approach to deprescribing in care homes. Care Home Pharmacy Team. Herts Valleys Clinical Commissioning Group

The In-betweeners: What to do with problem gamblers with mental health problems. Neil Smith National Problem Gambling Clinic CNWL NHS Trust

2012 Chronic Respiratory. Program Evaluation. Our mission is to improve the health and quality of life of our members

Monitoring Psychotropic Use Among Foster Children EMPAA

2017 Chronic Respiratory. Program Evaluation. Our mission is to improve the health and quality of life of our members

Bipolar Disorder Clinical Practice Guideline Summary for Primary Care

PBMs: Impact on Cost and Quality of Pharmaceutical Care in the U.S.

Genomind and The Genecept Assay

Improving Mental Health Care: A Case Study

2017 Diabetes. Program Evaluation. Our mission is to improve the health and quality of life of our members

CASE 5 - Toy & Klamen CASE FILES: Psychiatry

Effects of Home Antipsychotic Reinitiation in ICU Patients with a History of Mental Illness

emeasure Titles and Descriptions

Texas Council Endorsed Measurement Strategy

SUMMARY TABLE OF MEASURE CHANGES

Psychotropic Medication Utilization Review (PMUR) Process for STAR Health Members

6/22/2012. Co-morbidity - when two or more conditions occur together. The two conditions may or may not be causally related.

Pediatric Psychopharmacology

Curbing the High Rates of Psychotropic Medication Prescriptions among Children and Youth in Foster Care

CY 2017 MMA Performance Measure Scores HEDIS, Core Set, and Agency-defined measures

Prevalence of Comorbidity and Pattern Drug Use among Children with Attention-deficit hyperactivity disorder: A Single Center in Thailand

Antidepressants for treatment of depression.

Help and Healing: Section 2: Treatment Planning. Treatment and Timelines. Depression Treatment Reference. Care Team Communication

MSPPS Clinical Focus Areas

Goal: To learn about and evaluate the value of various biologically-based methods in the treatment of different forms of psychopathology

Patient Review and Coordination Program

Integrating INTERACT into Interim Pharmacist Reviews

9/11/2012. Clare I. Hays, MD, CMD

Depression Disease Navigation

November Data Jam. Mastering PSYCKES: Maximizing Multiple Data Sources to Operationalize a Population Health Approach

Monitoring Protocol for Clozapine-induced Myocarditis. Copyright 2017, CAMH

Major Depressive Disorder (MDD) in Children under Age 6

Curbing Prescription Drug Abuse in Medicaid

2017 URAC PHARMACY BENEFIT MANAGEMENT PERFORMANCE MEASUREMENT: AGGREGATE SUMMARY PERFORMANCE REPORT

Changes for Physician Measurement 2018

ENSURING EXCELLENCE IN PRESCRIBING FOR OLDER ADULTS

REACH VET and the Possible Impact on Integrated Healthcare

Curriculum Vitae, Michael J. Downing, M.D.

MODEL PSYCHOPHARMACOLOGY CURRICULUM

Piecing the Puzzle Together: Pharmacologic Approaches to Behavioral Management in Autism Spectrum Disorder

Medication Management. Dr Ajith Weeraman MBBS, MD (Psychiatry), FRANZCP Consultant Psychiatrist Epworth Clinic Camberwell 14 th March 2015

th Street, NW Suite 1000 Washington, DC phone fax

A Retrospective Claims Analysis of Medication Adherence and. Persistence Among Patients Taking Antidepressants

Mending the Mind: treatment of the severely mentally ill

Psychotropic Medication

RxVACCINATE: A National Education and Practice Support Initiative to Increase Pharmacist Administered Pneumococcal Vaccinations.

Making the Business Case for Long-Acting Injectables

How to Conduct an Effective Medication Therapy Management Session in the Community Pharmacy

Aging with Bipolar Disorder. Neha Jain, MD, FAPA Assistant Professor of Psychiatry, UConn Health

KEY BEHAVIORAL MEASURES

VO- PMHP Treatment Guideline 102: Electroconvulsive Therapy (ECT)

Psychosis & Schizophrenia: The Updated NICE Quality Standard. Dr Tony Gill Mental Health Practitioner University of Leeds 7 th June 2015

B. Executive Summary. Category: Cross Boundary Collaboration and Partnerships Page 2 of 7

Schizophrenia, a devastating chronic. Treatment Adherence Associated With Conventional and Atypical Antipsychotics in a Large State Medicaid Program

Psychotropic Medication. Including Role of Gradual Dose Reductions

To Take or Not To Take?

Ambulatory Cardiac Monitoring Modalities

E-Prescribing, EPCS & PDMP: An Update

Reach Out to Patients for Better Disease Management

Mental Health Subcommittee of PTAC meeting held 21 June (minutes for web publishing)

PGEU GPUE. Pharmaceutical Group of European Union Groupement Pharmaceutique de l Union Européenne

HOPE Agenda. Heroin, Opioid Prevention & Education WISCONSIN STATE REPRESENTATIVE JOHN NYGREN ASSEMBLY DISTRICT 89

Improving Dementia Care in Nursing Homes Through Best Care Practices

Advocating for people with mental health needs and developmental disability GLOSSARY

Pediatric Primary Care Mental Health Specialist Certification Exam. Detailed Content Outline

Estimate of the Net Cost of A Prior Authorization Requirement for Certain Mental Health Medications. Prepared by. Driscoll & Fleeter.

Presenter. Rebecca Susic Director Account Management MEDai

Review: Psychosocial assessment and theories of development from N141 and Psych 101

Transcription:

Introducing ValueOptions Clinical Care Alerts January 2013

Agenda What are Clinical Care Alerts? How does it work? What are the benefits? Questions and Answers 2

The Issue of Poor Medication Adherence Unnecessary hospitalizations Medication escalation 3

The Impact of Non-Adherence Medication-related problems contribute up to 50% of behavioral health admissions, 20% of medical admissions, and increased morbidity and mortality. Medication non-adherence is considered the single most important factor leading to relapse among patients with schizophrenia. Risk of hospitalization for schizophrenia decreases by almost 20% for every 10% increase in medication compliance. Patients with therapy gaps of 30 or more days per prescription have almost five times greater risk of being hospitalized compared with patients whose therapy gaps are 0 to 10 days. American Health & Drug Benefits, August 2009 4

Most Interventions Today Target Patients Directly Physician Research shows patient self-reporting to be highly unreliable. 1 Patient Health Plan PBM Pharmacy 5

Clinical Care Alerts Our Clinical Care Alert automated system identifies and notifies physicians of potential behavioral health, physical health, and medication care gaps in a timely manner. It re-engages physicians in what has become an increasingly member-centric world to close patient-specific care gaps in the entire population while improving quality. 6

Clinical Care Alerts Help Close Care Gaps Works through the patient s trusted advisor the physician closing a key feedback loop Most often closed care gap is Early Discontinuation of Medication Enhances provider collaboration by notifying all physicians related to a specific issue 7

Automated Provider Engagement Behavioral Claim Data ValueOptions Clinical Care Alert Physician Patient 8

Concise Alerts that Support Collaborative Care Sample Medication Adherence Alert 9

Concise Alerts that Support Collaborative Care Sample Lab Monitoring Alert 10

Clinical Care Alert Technology Analytical tools consisting of field-tested, validated rule sets for successful conversion that drives overall cost savings Uses 11,000+ alert rules to screen the entire population and intervene earlier to reduce the chance of consumers becoming high-risk and high-cost Alert rules updated manually on a bi-monthly basis or as needed Enhances provider collaboration by notifying all physicians related to the specific issue in writing so they can work together to coordinate care for the consumer Automated alert generation leads to successful intervention Customized nimble, flexible data exchange structure 11

Clinical Care Alert Automated Process 12

Alert Rules Cover All Chronic Conditions Poor Compliance Early Discontinuation Sub-Optimal Therapy Duplicate Therapy Missing Procedures Alerts Polypharmacy Monitoring Drug-Drug Interactions Age-Inappropriate Therapy Overuse / Substance Abuse 13

Behavioral Health Related Rules Alert Depression Without Antidepressants Follow-Up After Hospitalization for Mental Illness Acute and Continuation Phase Depression Treatment Optimal Practitioner Contacts for Medication Management of Depression Medications that Aggravate Depression Schizophrenia Without Antipsychotics Antipsychotic medications & metabolic screening Bupropion & Eating Disorders Bipolar Disorder Without Mood Stabilizers ADHD Medication Management Example Diagnosed with depression but is not filling prescriptions for an anti-depressant. Consumers hospitalized for treatment of selected mental health disorders but not seen on an ambulatory basis or in intermediate treatment with a mental health provider. Consumers diagnosed with a new episode of depression were treated with antidepressant medication, but discontinued therapy prior to six months. Consumers diagnosed with a new episode of depression and treated with antidepressant medication, but have not had at least three follow-up contacts with a practitioner during the 84-day (12-week) Acute Treatment Phase. Multiple drugs have been reported to cause depression in some consumers. Elderly people are particularly at risk. Consumer appears to have schizophrenia but is not filling prescriptions for an antipsychotic. Consumers treated with an atypical antipsychotic agent that have not had a diabetes screening. Combination bupropion and eating disorder increasing risk of seizures. Consumer appears to have a bipolar disorder, but is not filling prescriptions for a mood stabilizer. Attention deficit hyperactivity disorder (ADHD) consumers on first-line medication that have less than one (1) follow-up visit per year. 14

Questions and Answers